share_log

Merck & Co | 4: Statement of changes in beneficial ownership of securities-Officer Li Dean Y

SEC announcement ·  Feb 13 05:08
Summary by Futu AI
Li Dean Y, Executive VP & President of Merck & Co's MRL division, completed a sale of 14,702 shares of the company's common stock on February 9, 2024. The shares were sold at an average price of $125.4988, resulting in a total transaction value of approximately $1.85 million. Following the sale, Li's direct holdings in Merck & Co. amounted to 46,242.37 shares. The transaction was executed as an open market or private sale, following an acquisition of the same number of shares through the exercise or conversion of derivative security at a price of $62.07 per share.
Li Dean Y, Executive VP & President of Merck & Co's MRL division, completed a sale of 14,702 shares of the company's common stock on February 9, 2024. The shares were sold at an average price of $125.4988, resulting in a total transaction value of approximately $1.85 million. Following the sale, Li's direct holdings in Merck & Co. amounted to 46,242.37 shares. The transaction was executed as an open market or private sale, following an acquisition of the same number of shares through the exercise or conversion of derivative security at a price of $62.07 per share.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.